Result
€500,241 ▲ 52.2%
The result rose in 2025: different schema filed.
ExpansionPharma
Lifetime
12 annual accounts with figures on one time axispeak €973,166 (2025)
€973,166▲ 53.0%
lowest -€48,927 (2021)
€500,241▲ 52.2%
peak €6.6m (2025)
€6.6m▲ 8.2%
€3.3m▼ 3.9%
peak 4.8 FTE (2025)
4.8 FTE▲ 60.0%
Board2 names since 2021
2 directors and 1 other
Documentsfilings and deeds
20-08-202620 days late
2025abbreviated format
Gross margin from €635,953 to €973,166Result from €328,759 to €500,241Staff from 3 FTE to 4.8 FTEInvestments €193,219Cash from €36,018 to €57,257
Key points
from the 2025 annual accountsInvestments
€193,219 3.3 × depreciation
Green is investment, beige is depreciation. Land and buildings stand 36.5% higher than in 2024.
Staff
9 employees on 31-12-2025
In 2025, 11 people joined and 5 left.
Filings
12 annual accounts since 2014
Seven of the last ten came late. The 2017 accounts came latest: 59 days after the end of the period.
Subsidiaries
-€745,658
Subsidiary with negative equity. · loss of €122,242 in 2025 · 2 other subsidiaries too.
Group
8 companies controlled
Heads a group.
Checked score
Outside the general model
Model not applicable to financial institutions
The Checked score measures liquidity, leverage and margins against the norms for trading and manufacturing companies. A bank, insurer or financial holding has a very different balance sheet. Those ratios and the score mean nothing here. So there is no financial strength either.
Bankruptcy probability within 12 months
The company is a financial institution: a bank, insurer or financial holding. Its balance sheet works differently from that of a trading or manufacturing company. A bankruptcy probability from the general model would mislead here.
Credit check for an amount and term of your choice
Show the recommended maximum and see how the verdict changes with amount, term and advance.
The scores and ratios are Checked's own calculations, not a credit decision.
Signals
Board and ownership
Director
Director
- 2,833 sharesdeed of 18-01-2017
- 2,833 sharesdeed of 18-01-2017
Shares in 7 companies, including and
Board & ownershipRecent changes
Registered in the Peppol Directory
Reachable for e-invoices through 0208:0536620925
Registered office moved within Arlon
New registered office: rue de l’Abattoir 1, 6700 Arlon · Previous registered office: Route de Luxembourg, 97 6700 Arlon · Appointments: (statutory director) and (statutory director) · General meeting of 09-09-2022 · Gazette deed
Registered office moved from Aubange to Arlon
New registered office: Route de Luxembourg, 97 6700 Arlon · Previous registered office: Avenue de la Gare 3, 6790 Aubange · Board meeting of 29-03-2018 · Gazette deed
Capital increase of €4,844,601.52 to €4,863,201.52
Capital of €4,863,201.52, 5,852 shares · Capital from €18,600 to €4,863,201.52, 5,666 new shares · Capital contribution: apport pleine propriété · General meeting of 21-12-2016 · Gazette deed
Comparable companies
same main activity, similar in size and age| Company | ||||
|---|---|---|---|---|
| ExpansionPharma Arlon | €9.9m | €1.0m | 66.3% | 4.8 |
| MIR HOLDING Dendermonde | €9.7m | €1.0m | 90.6% | 6 |
| MIMMO INVEST Izegem | €13.9m | €1.0m | 6.5% | 3.6 |
| QUADRO HOLDING Bilzen-Hoeselt | €11.5m | €1.0m | -9.9% | 6.9 |
| Wanaka Partners Antwerp | €12.1m | €0.7m | 85.1% | 3.8 |
| INFRAPROJECT Oosterzele | €9.6m | €0.9m | 91.8% | 3.9 |
| FERROMAC GROUP Antwerp | €14.1m | €0.7m | 70.3% | 4.5 |
These companies have the same main activity as ExpansionPharma: activities of holding companies (NACE 64210). They are comparable in size and age: total assets between €9.6m and €14m, founded between 2009 and 2014.
Official details
Source: KBO- Status
- Active since 10-07-2013Normal situation
- Activity
- Activities of holding companiesNACE 64210and 1 other
- Joint committees
- 100Auxiliary committee for blue-collar workers
- 210White-collar workers in the steel industry · annual accounts 2025
- Establishment unit
- 2.224.270.0796700 Arlon, since 06-07-2013
- Financial year end
- 31 December
- Peppol
- Reachable since 26-01-2026
Companies linked to ExpansionPharma
Subsidiaries and holdings
- 100%
- 100%
- 99.92%
- 99%
- 98%
Insights on ExpansionPharma
ExpansionPharma files the abbreviated format. That format states no turnover. The gross margin rose from -€3,023 in 2014 to €973,166 in 2025.
Sources: KBO register, filings at the National Bank, Belgian Official Gazette. Click a figure with a dotted line for the item and the filing.
Key facts about ExpansionPharma
- What is the company number of ExpansionPharma?
- The company number of ExpansionPharma is 0536.620.925. The VAT number is the same number with BE in front: BE 0536.620.925.
- Where is ExpansionPharma based?
- The registered office is at Rue de l'Abattoir 1, 6700 Arlon.Company details
- What does ExpansionPharma do?
- According to the KBO register, the main activity is activities of holding companies (NACE 64210).
- What is the legal form of ExpansionPharma?
- ExpansionPharma is a private limited company (BV).
- When was ExpansionPharma founded?
- ExpansionPharma was founded on 10-07-2013.
- Is ExpansionPharma still active?
- Yes, ExpansionPharma is an active enterprise in the KBO register.
- How many employees does ExpansionPharma have?
- ExpansionPharma had an average of 4.8 full-time equivalents in financial year 2025, according to the filed annual accounts.Financials
- Which joint committee does ExpansionPharma fall under?
- In its 2025 annual accounts, ExpansionPharma states joint committees 100 (Auxiliary committee for blue-collar workers) and 210 (White-collar workers in the steel industry).
- What is the turnover of ExpansionPharma?
- The turnover in financial year 2025 is ≈ €1.3m. This figure is estimated from the gross margin of €973,166 and 34 comparable companies (NACE 64210). It probably lies between €1.1m and €2.0m. In financial year 2019 turnover was €63,737.
- Is ExpansionPharma profitable?
- In financial year 2025, ExpansionPharma made a profit of €500,241.
- Where can I find the annual accounts of ExpansionPharma?
- ExpansionPharma filed 12 annual accounts with the National Bank of Belgium, the latest for financial year 2025.
- When are the next annual accounts of ExpansionPharma due?
- ExpansionPharma must file the annual accounts for financial year 2026 by 31-07-2027.Timeline
Next steps
Work out how much credit to give this customer and on what payment terms.Credit check Check what to know before you do business with this company.Supplier due diligence Check whether you can accept this company as a client under the anti-money-laundering law.AML client file Check which of your other customers you can e-invoice via Peppol.Peppol check See the other companies in the same group.ExpansionPharma · 9 companies See what changed in the latest annual accounts.What changed
See how customers, suppliers and banks see your own company and what to improve first.